Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone

Blood

Volumn 95, Issue 5, 2000, Pages 1580-1587

  Raza, Azra ^a   Qawi, Huma ^b   Lisak, Laurie ^b   Andric, Tanja ^b   Dar, Saleem ^b   Andrews, Colleen ^b   Venugopal, Paramesuaran ^b   Gezer, Sefer ^b   Gregory, Stephanie ^b   Loew, Jerome ^b   Robin, Erwin ^b   Rifkin, Shelby ^b   Hsu, Wei Tong ^b   Huang, Ray Win ^b  

^a RUSH CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CIPROFLOXACIN; DEXAMETHASONE; PENTOXIFYLLINE; RADIOPROTECTIVE AGENT;

ADULT; AGED; ANOREXIA; ANXIETY; ARTICLE; CELL PROTECTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DEPRESSION; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; FOLLOW UP; HUMAN; HYPOTENSION; LEUKOCYTE COUNT; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; PALLIATIVE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA; THROMBOCYTE COUNT; VOMITING;

EID: 0034161542     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.5.1580.005k45_1580_1587     Document Type: Article

References (40)

1. Cazzola M, Anderson JE, Ganser A, Hellstrom-Lindberg E. A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica. 1998;83:910-935.
2. Santini V, Ferrini PR. Differentiation therapy of myelodysplastic syndromes: fact or fiction? [review]. Br J Haematol. 1998;102:1124-1138.
3. Ratanatharathom V, Karanes C, Uberti J, et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood. 1993;81:2194-2199.
4. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. Blood. 1996;87:51-58.
5. Vadhan-Raj S, Keating M, Lemaistre A, et al. Effects of recombinant human granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987;317:1545-1552.
6. Negrin RS, Haiber DH, Nagler A, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood. 1990;76:36-43.
7. Greenberg P, Taylor K, Larson R, et al. Phase III randomized multicenter trial of G-CSF vs observation for myelodysplastic syndromes (MDS). Blood. 1993;82(suppl 1):196a.
8. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: an analysis of 205 patients in 17 studies. Br J Haematol. 1995;89:67-71.
9. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase 11 study and long-term follow-up of 71 patients. Blood. 1998;92:68-75.
10. Hermann F, Lindemann A, Klein H, et al. Effect of recombinant human granulocyte macrophage colony-stimulating factor in patients with myelodysplastic syndromes with excess blasts. Leukemia. 1989;3:335-338.
11. Cheson BD. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res. 1998;22:17-21.
12. Hiddemann W, Jahns-Streubel G, Verbeek W, Wormann B, Haase D, Schoch C. Intensive therapy for high-risk myelodysplastic syndromes and the biologic significance of karyotype abnormalities. Leuk Res. 1998;22:23-26.
13. Clark DM, Lampert IA. Apoptosis is a common histopathological finding in myelodysplasia: the correlate of ineffective hematopoiesis. Leuk Lymphoma. 1990;2:415-418.
14. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995;86:268-276.
15. Bogdanovic AD, Jankovic GM, Colovic MD, Trpinac DP, Bumbasivevic VZ. Apoptosis in bone marrow of myelodysplastic patients. Blood. 1995;86:268-276.
16. Bouscary D, De Vos J, Guesnu M, et al. Fas/ Apo-I (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia. 1997;11:839-845.
17. Mundle SD, Venugopal P, Pandav DV, et al. Indication of an involvement of interleukin-Iβ converting enzyme (ICE)-like protease in intramedullary apoptotic cell death in the bone marrows of patients with myelodysplastic syndromes (MDS). Blood. 1996;8:2640-2647.
18. Shetty V, Mundle S, Alvi S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996;20:891-900.
19. Kitagawa M, Saito I, Kuwata T, et al. Overexpression of tumor necrosis factor alpha and interferon gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. 1997;11:2049-2054.
20. Veerhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia. 1992;6:1268-1272.
21. Bursten W, Weeks R, West J, et al. A potential role for phosphatidic acid in mediating the inflammatory responses of TNF-α and IL-1β. Circ Shock. 1994;44:14-19.
22. Dezube BJ, Pardee AB, Chapman B, et al. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J Acquir Immune Defic Syndr. 1993;6:787-794.
23. Thompson JA, Bianco JA, Benyunes MC, Neubauer MA, Slattery JT, Fefer A. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine activated killer cell therapy for metastatic renal carcinoma. Cancer Res. 1994;54:3436-3441.
24. Doherty GM, Jensen JC, Alexander R, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;8:192-198.
25. Nemunaitis J, Rosenfeld C, Getty L, et al. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome: a phase 11 trial. Am J Clin Oncol. 1993;18:189-194.
26. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis in the signaling pathway. J Exp Med. 1990;172:391-394.
27. Raza A, Venugopal P, Gezer S, et al. Pilot study of pentoxifylline and ciprofloxacin with or without dexamenthasone produces encouraging results in myelodysplastic syndromes: acute leukemias VII. In: W. Hiddemann, T. Buchner, B. Wormann, et al, eds. Experimental Approaches and Novel Therapies. New York: Springer-Verlag; 1998:42-51.
28. Reza S, Shetty V, Dar S, Qawi H, Raza A. Tumor necrosis factor alpha levels decrease with anti-cytokine therapy in patients with myelodysplastic syndromes. J Interferon Cytokine Res. 1998;18:871-877.
29. List AF, Brasfield F, Heaten R, et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndromes. Blood. 1997;90:3364-3369.
30. Negrin RS, Stein R, Vardiman J, et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor in combination with erythropoietin. Blood. 1993;82:737-743.
31. Janssen JWG, Buschle M, Layton M, et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood. 1989;73:248-254.
32. Raza A, Gregory SA, Preisler HD. The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk Res. 1996;20:881-890.
33. Glover D, Glick JH, Weiler C, Hurowitz S, Kligermann MM. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase 11 trial. J Clin Oncol. 1986;4:574-578.
34. Kemp G, Rose P, Lurain J, et al. Amifostine pre-treatment for protection against cyclophospamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101-2112.
35. List AF, Heaton R, Glinsmann-Gibson B, Capizzi RL. Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia. 1998;12:1596-1602.
36. Preisler HD, Li B, Yang J, et al. Suppression of telomerase activity and cytokine mRNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and IL4. Clin Cancer Res. In press.
37. Bowen DT, Denzlinger C, Brugger W, et al. Poor response rate to a continuous schedule of amifostine therapy for low/intermediate risk myelodysplastic patients. Br J Haematol. 1998;103:785-787.
38. Bagby Jr GC. Mechanism of glucocorticosteroid activity in patients with the preleukemic syndrome (hemopoietic dysplasia). Leuk Res. 1980;4:571-580.
39. Raza A. The initial transforming event in myelodysplastic syndromes may be viral: the case for cytomegalovirus. Med Oncol. 1998;15:165-173.
40. Raza A. Hypothesis: myelodysplastic syndromes may have a viral etiology. Int J Hematol. 1998;68:245-256.